Antibodies In-Depth Focus 2017
Posted: 15 March 2017 | Drug Target Review | No comments yet
Lone Friis and David Matthews discuss developability assessment of therapeutic antibodies, and Negin Mokhtari and colleagues explain nanoparticle-mediated enzyme delivery for application in cancer therapy…
Included in this Antibodies In-Depth Focus:
- Developability assessment of therapeutic antibodies
Lone Friis and David Matthews – MRC Technology Centre for Therapeutics Discovery - Antibody-based immunooncology: hopes and perils
Ismael Samudio, The Centre for Drug Research and Development (CDRD) and Gregorio Aversa, Immcure Theraputics
This Antibodies In-Depth Focus is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Antibodies, Antibody Discovery, Immuno-oncology, Immuno-oncology therapeutics, Therapeutics
Related conditions
Cancer
Related organisations
Immcure Theraputics, MRC Technology, The Centre for Drug Research and Development (CDRD)
Related people
David Matthews, Gregorio Aversa, Ismael Samudio, Lone Friis
